Registration Header

Compound Delivery, PK-PD, & Validation Studies in Oncology Research
Programmable Pumps for Compound Delivery in Rodent in vivo Models

Speaker: Christian Schnell, Associate Director Oncology, Novartis

Duration:60 minutes

Over the past decade, there is increasing interest in establishing a robust mechanistic understanding of the pharmacokinetics–pharmacodynamics (PK–PD) relationship of a given compound and its connection to the anti-tumor efficacy profile.

In this webinar, Christian will describe the validation studies performed in his pharmacology unit in rats and mice. Accurate PK-PD assessment and corresponding antitumor activity were assessed among several drug discovery programs. He provides evidence that the investigation of such compound specific relationships are a pre-requisite for the planning of meaningful efficacy studies in preclinical models and the subsequent translation into patient’s clinical trials.

Taking into account best practices and the 3Rs of animal research (Reduction, Refinement and Replacement), implantable pumps are one of the most effective ways to deliver drugs without interfering with normal animal activity, especially in a group-housed environment. Long term, chronic dosing regimens and quantitative pharmacology for PK-PD may be scheduled and executed with minimal human intervention and animal stress, and in doing so reducing the impact of these important confounding factors. Therefore, data variability will be lower leading to reduction of animal use. Moreover, it should be emphasized that the simultaneous use of complementary novel technologies within the same animal (like radio-telemetry and programmable pumps as described here) will enable advances in the understanding of complex physiological regulation mechanism following pharmacological intervention, possibly leading to improved therapies in the clinic.
Live Date: 6/16/2021

Click the button below to access the login portal:



Christian Schnell

Associate Director Oncology NIBR


Christian joined NOVARTIS (previously CIBA-GEIGY) in 1980, first in Cardiovascular Research followed by Oncology Research since 1994. He was actively involved in the profiling of several compounds that entered the clinical development and reached the market like DIOVAN®, RASILEZ®, GLEEVEC®, ZOMETA®, AFFINITOR® and PIQRAY ®. Christian was one of the first to adapt fully implantable telemetry devices for blood pressure and ECG recordings in conscious unrestrained marmosets (1993), for intraocular pressure measurements in the vitreous of conscious unrestrained rabbits (1996), and for the measurement of tumour interstitial pressure in conscious unrestrained rats and mice (2003). Currently, he is the 3R’s representative for Oncology Basel at Novartis.
First Name
Last Name
Company Email Address
Job Title

By completing and submitting this registration, you agree to receive occasional e-mail or other contact from InsideScientific and the sponsors associated with this webinar about their respective programs and products including but not limited to product information, news, events and other offers. The program sponsor(s) and InsideScientific agree to not rent, sell, exchange, or give your information to any third party without permission. You may opt out of emails at any time. By submitting this registration you confirm that you have read and agree to associated Privacy Policies.

© 2021 InsideScientific. All rights reserved.